A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Study of Drug VK2809 in Patients with Primary Hypercholesterolemia and Non-Alcoholic Fatty Livery Disease
Sponsor: Viking Therapeutics, Inc.
Enrolling: Male and Female Patients
Study Length: 16 Weeks
IRB Number: AAAR5964
U.S. Govt. ID: NCT02927184
Contact: Ali Andre Mencin MD: 212-305-5903 / am2363@cumc.columbia.edu
Additional Study Information: This study is a multicenter study to assess the efficacy, safety, and tolerability of vk2809 administered for12 weeks followed by a 4-week off-drug Phase in subjects with primary hypercholesterolemia and nonalcoholic Fatty liver disease. This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of the treatment period (Week 12).
This study is closed
Investigator
Ali Mencin, MD
Do You Qualify?
Are you willing and able to give written informed consent? Yes No
Do you have hyperlipidemia or non-alcoholic fatty liver disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Ali Andre Mencin MD
am2363@cumc.columbia.edu
212-305-5903
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE